<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36944811</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1970-9366</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Internal and emergency medicine</Title><ISOAbbreviation>Intern Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact.</ArticleTitle><Pagination><StartPage>801</StartPage><EndPage>809</EndPage><MedlinePgn>801-809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11739-023-03228-5</ELocationID><Abstract><AbstractText>With the goal to increase knowledge on the healthcare impact of the post-COVID-19 condition we exploited the administrative claims database of Lombardy, the largest Italian region and the first after China to be heavily hit by the SARS-CoV-2 pandemic in February-May 2020. We chose to employ the dispensation of drugs and diagnostic tests as proxies of the impact of the post-COVID condition in 46,574 cases who recovered from COVID-19 and were negative at PCR testing within June 20, 2020. Data were obtained throughout the 18-month post-negativization period until December 2021 and results on the use of drugs and diagnostic tests were compared with those accrued in the same cases during the pre-COVID period in July-December 2019. After an increase in the first semester after SARS-CoV-2 negativization (July-December 2020), trends in the dispensation of drugs according to the broad ATC classes and of diagnostic tests decreased or remained substantially stable. However, dispensation of drugs for acid related disorders (A02), diabetes (A10), heparins (B01AB), direct oral anticoagulants (B01AP), antipsychotics (N05A), antidepressants (N06A) and for obstructive airways diseases (R03) was still higher than in the pre-COVID period. These findings, based upon drug and diagnostic test dispensation as proxies of the healthcare impact of the post-COVID condition, show that in a substantial proportion of recovered cases the post-COVID condition is active and clinically relevant 18&#xa0;months after the acute disease. The findings also provide indirect evidence of the body organs and systems more compromised in the post-COVID period.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Societ&#xe0; Italiana di Medicina Interna (SIMI).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7813-0572</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy. alessandro.nobili@marionegri.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Avanzo</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tettamanti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galbussera</LastName><ForeName>Alessia Antonella</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remuzzi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortino</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Direzione Generale Welfare, Regione Lombardia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Direzione Generale Welfare, Regione Lombardia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences and Community Health, Universit&#xe0; Di Milano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Internal Medicine, Multimedica IRCSS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannucci</LastName><ForeName>Pier Mannuccio</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DGR n. 3375 - July 14</GrantID><Agency>Regione Lombardia</Agency><Country/></Grant><Grant><GrantID>2020</GrantID><Agency>Regione Lombardia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Intern Emerg Med</MedlineTA><NlmUniqueID>101263418</NlmUniqueID><ISSNLinking>1828-0447</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003955" MajorTopicYN="N">Diagnostic Tests, Routine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Administrative database</Keyword><Keyword MajorTopicYN="N">Anticoagulants</Keyword><Keyword MajorTopicYN="N">Antipsychotic drugs</Keyword><Keyword MajorTopicYN="N">COPD</Keyword><Keyword MajorTopicYN="N">Clinical sequels</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Polypharmacy</Keyword></KeywordList><CoiStatement>None of the authors declares to have conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36944811</ArticleId><ArticleId IdType="pmc">PMC10030070</ArticleId><ArticleId IdType="doi">10.1007/s11739-023-03228-5</ArticleId><ArticleId IdType="pii">10.1007/s11739-023-03228-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) https://www.cdc.gov/nchs/icd/icd9cm.htm</Citation></Reference><Reference><Citation>CDC Announces Approval of ICD-10 Code for Post-Acute Sequelae of COVID-19. https://www.cdc.gov/nchs/icd/icd10cm.htm. At least 17 million people in the WHO European Region experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come. https://www.who.int/europe/news/item/13-09-2022-at-least-17-million-people-in-the-who-european-region-experienced-long-covid-in-the-first-two-years-of-the-pandemic--millions-may-have-to-live-with-it-for-years-to-come</Citation></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11(2):269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Yan MZ, Li X, Lau EHY. Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis. Infection. 2022 doi: 10.1007/s15010-022-01862-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01862-3</ArticleId><ArticleId IdType="pmc">PMC9244338</ArticleId><ArticleId IdType="pubmed">35750943</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, Obeidat M, Obeidat Y, Gerberi D, Taha RM, Kashour Z, Kashour T, Berbari EF, Alkattan K, Tleyjeh IM. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramirez DC, Normand K, Zhaoyun Y, Torres-Castro R. Long-term impact of COVID-19: a systematic review of the literature and meta-analysis. Biomedicines. 2021;9(8):900. doi: 10.3390/biomedicines9080900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080900</ArticleId><ArticleId IdType="pmc">PMC8389585</ArticleId><ArticleId IdType="pubmed">34440104</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer N, Bart B, Billington CJ, et al. COVID-19 postacute care major organ damage: a systematic review. BMJ Open. 2022;12:e061245. doi: 10.1136/bmjopen-2022-061245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061245</ArticleId><ArticleId IdType="pmc">PMC9412042</ArticleId><ArticleId IdType="pubmed">36002211</ArticleId></ArticleIdList></Reference><Reference><Citation>Casti E, Adobati F, Negri I, editors. Mapping the epidemic. A systemic geography of COVID-19 in Italy. Amsterdam: Elsevier; 2021. pp. 1&#x2013;230.</Citation></Reference><Reference><Citation>Mannucci PM, Nobili A, Tettamanti M, D'Avanzo B, Galbussera AA, Remuzzi G, Fortino I, Leoni O, Harari S. Impact of the post-COVID-19 condition on health care after the first disease wave in Lombardy. J Intern Med. 2022;292(3):450&#x2013;462. doi: 10.1111/joim.13493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13493</ArticleId><ArticleId IdType="pmc">PMC9115275</ArticleId><ArticleId IdType="pubmed">35373863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannucci PM, Nobili A, Tettamanti M, D'Avanzo B, Galbussera AA, Remuzzi G, Fortino I, Leoni O, Harari S. Progressive decrease of the healthcare impact of the post-COVID condition after the first disease wave in Lombardy, Italy. J Intern Med. 2022 doi: 10.1111/joim.13554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13554</ArticleId><ArticleId IdType="pmc">PMC9538040</ArticleId><ArticleId IdType="pubmed">35968565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431&#x2013;2440. doi: 10.1056/NEJMoa2006923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2006923</ArticleId><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>ATC/DDD Index 2021 https://www.whocc.no/atc_ddd_index/</Citation></Reference><Reference><Citation>International classification of diseases, Ninth Revision, Clinical Modification (ICD-9-CM) https://www.cdc.gov/nchs/icd/icd9cm.htm</Citation><ArticleIdList><ArticleId IdType="pubmed">10310139</ArticleId></ArticleIdList></Reference><Reference><Citation>Robusto F, Lepore V, D'Ettorre A, Lucisano G, De Berardis G, Bisceglia L, et al. The Drug Derived Complexity Index (DDCI) predicts mortality, unplanned hospitalization and hospital readmissions at the population level. PLoS ONE. 2016;11(2):e0149203. doi: 10.1371/journal.pone.0149203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149203</ArticleId><ArticleId IdType="pmc">PMC4760682</ArticleId><ArticleId IdType="pubmed">26895073</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol. 2020;76(3):459&#x2013;465. doi: 10.1007/s00228-019-02815-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-019-02815-w</ArticleId><ArticleId IdType="pubmed">31853593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima K, Almas T, Lakhani S, Jahangir A, Ahmed A, Siddiqui A, Rahim A, Qureshi SA, Arshad Z, Golani S, Musheer A. The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop Med Infect Dis. 2022;7(3):37. doi: 10.3390/tropicalmed7030037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed7030037</ArticleId><ArticleId IdType="pmc">PMC8950138</ArticleId><ArticleId IdType="pubmed">35324584</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, Tkachuk VA, Markov AG, Lehnert H, de Angelis MH, Rietzsch H, Rodionov RN, Khunti K, Hopkins D, Birkenfeld AL, Boehm B, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH, Alberti KGMM, Geloneze B, Chan JC, Mbanya JC, Onyegbutulem HC, Ramachandran A, Basit A, Hassanein M, Bewick G, Spinas GA, Beuschlein F, Landgraf R, Rubino F, Mingrone G, Bornstein SR. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9(11):786&#x2013;798. doi: 10.1016/S2213-8587(21)00244-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00244-8</ArticleId><ArticleId IdType="pmc">PMC8489878</ArticleId><ArticleId IdType="pubmed">34619105</ArticleId></ArticleIdList></Reference><Reference><Citation>Oguz SH, Okan Yildiz B. Endocrine disorders and COVID-19. Annu Rev Med. 2022 doi: 10.1146/annurev-med-043021-033509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-043021-033509</ArticleId><ArticleId IdType="pubmed">36151047</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybowska M, Wyrostkiewicz D, Opoka L, Lewandowska K, Sobiecka M, Tomkowski W, Szturmowicz M. Venous thromboembolic disease in COVID-19, pathophysiology, therapy and prophylaxis. Int J Mol Sci. 2022;23(18):10372. doi: 10.3390/ijms231810372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231810372</ArticleId><ArticleId IdType="pmc">PMC9499629</ArticleId><ArticleId IdType="pubmed">36142282</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC. Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. Expert Rev Hematol. 2022;15(7):597&#x2013;605. doi: 10.1080/17474086.2022.2098104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2022.2098104</ArticleId><ArticleId IdType="pubmed">35786377</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021;8(7):e524&#x2013;e533. doi: 10.1016/S2352-3026(21)00105-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00105-8</ArticleId><ArticleId IdType="pmc">PMC8078884</ArticleId><ArticleId IdType="pubmed">33930350</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC) Cardiovasc Diabetol. 2022;21(1):148. doi: 10.1186/s12933-022-01579-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Vai B, Mazza MG, Marisa CD, Beezhold J, K&#xe4;rkk&#xe4;inen H, Saunders J, Samochowiec J, Benedetti F, Leboyer M, Fusar-Poli P, De Picker L. Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health. Eur Psychiatry. 2022;65(1):e47. doi: 10.1192/j.eurpsy.2022.2307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/j.eurpsy.2022.2307</ArticleId><ArticleId IdType="pmc">PMC9486830</ArticleId><ArticleId IdType="pubmed">35971656</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, Sirota M, Stevenson DK. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4(11):e2133090. doi: 10.1001/jamanetworkopen.2021.33090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.33090</ArticleId><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgis RR, Lieberman JA. Anti-viral properties of antipsychotic medications in the time of COVID-19. Psychiatry Res. 2021;295:113626. doi: 10.1016/j.psychres.2020.113626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113626</ArticleId><ArticleId IdType="pmc">PMC7833567</ArticleId><ArticleId IdType="pubmed">33290940</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. 2022;36(7):681&#x2013;702. doi: 10.1007/s40263-022-00931-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-022-00931-3</ArticleId><ArticleId IdType="pmc">PMC9210800</ArticleId><ArticleId IdType="pubmed">35727534</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza RF, Santos NO, Dos Santos FA, Ribeiro da Silveira P, Tiwari S, Alzahrani KJ, G&#xf3;es-Neto A, Azevedo V, Ghosh P, Barh D. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4):700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeloye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Heaney LG, Rudan I, Sheikh A, De Soyza A; International COVID-19 Airways Diseases Group (2021) The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med 9(12):1467&#x2013;1478</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8372501</ArticleId><ArticleId IdType="pubmed">34416191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonietto TA, Lincho CS, Marques LDS, Elsing J, da Silveira F, Fendt LCC, Montes THM, Dos Passos MG, Vargas T, Marin LG, Nedel WL. Influence of radiologic pattern and the presence of diffuse parenchymal lung disease on outcome in ventilated patients with COVID-19 pneumonia: impact on prognosis. Intern Med J. 2022 doi: 10.1111/imj.15912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15912</ArticleId><ArticleId IdType="pmc">PMC9538882</ArticleId><ArticleId IdType="pubmed">36053990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>